Psycho-neuroendocrine-immune interpretation of schizophrenia pathogenesis and treatment

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Medical Hypotheses

• Publication date

  2025-09-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.mehy.2025.111729
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of a Neuroimmune Therapy Including Pineal Methoxyindoles, Angiotensin 1-7, and Endocannabinoids in Cancer, Autoimmune, and Neurodegenerative Diseases

  2025cited by this paper
• Unraveling the role of brain renin angiotensin system in vascular dementia: mechanisms and therapeutic perspectives

  2025cited by this paper
• Therapeutic Potential of Enzymes, Neurosteroids, and Synthetic Steroids in Neurodegenerative Disorders: A Critical Review.

  2025cited by this paper
• Activation of central Angiotensin-(1-7)/Mas receptor alleviates synaptic damage in diabetes-associated cognitive impairment via modulating AKT/FOXO1/PACAP axis

  2025cited by this paper
• Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases.

  2025cited by this paper
• Psycho-Neuro-EndocrinE-Immunology Therapy of Cancer, Autoimmunity, Geriatric Disorders, Covid-19, and Hypertension.

  2025cited by this paper
• The differential effects of medicinal cannabis on mental health: A systematic review.

  2025cited by this paper
• Angiotensin-(1-7) protective effects in neurocognitive disorders: molecular mechanisms to therapeutic implications.

  2025cited by this paper
• Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research

  2025cited by this paper
• Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia

  2025cited by this paper
• Can artificial intelligence be the future solution to the enormous challenges and suffering caused by Schizophrenia?

  2025cited by this paper
• Sleep and circadian difficulties in schizophrenia: presentations, understanding, and treatment

  2025cited by this paper
• The role of cannabinoid-mediated signaling pathways and mechanisms in brain disorders.

  2025cited by this paper
• IUPHAR review: Drug Repurposing in Schizophrenia - An Updated Review of Clinical Trials.

  2025cited by this paper
• Mechanisms of vagus nerve stimulation for the treatment of neurodevelopmental disorders: a focus on microglia and neuroinflammation

  2025cited by this paper
• Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape

  2025cited by this paper
• Structural Features Influencing the Bioactive Conformation of Angiotensin II and Angiotensin A: Relationship between Receptor Desensitization, Addiction, and the Blood–Brain Barrier

  2024cited by this paper
• A cross-sectional report on the use of high doses of melatonin in humans.

  2024cited by this paper
• A Clinically Oriented Review of New Antipsychotics for Schizophrenia

  2024cited by this paper
• The Role of Neuroglia in the Development and Progression of Schizophrenia

  2024cited by this paper
• Advances in MRI Research for First-Episode Schizophrenia: A Selective Review and NSFC-Funded Analysis.

  2024cited by this paper
• REWRITALIZE your recovery: a study protocol for a randomised controlled trial (RCT) examining the effectiveness of the new recovery-oriented creative writing group intervention REWRITALIZE for people with severe mental illness

  2024cited by this paper
• Biological Methods for Diagnosing Depressive Symptoms in Patients with Schizophrenia: A Narrative Review

  2024cited by this paper
• Circulating inflammatory cytokines influencing schizophrenia: a Mendelian randomization study

  2024cited by this paper
• Endorphins, Sexuality, and Reproduction.

  2024cited by this paper
• Cognitive Effects of Electroconvulsive Therapy in Schizophrenia: A Systematic Review.

  2024cited by this paper
• Structural pharmacology and therapeutic potential of 5-methoxytryptamines

  2024cited by this paper
• Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen

  2024cited by this paper
• Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication

  2024cited by this paper
• The foundations of mind-body medicine: Love, good relationships, and happiness modulate stress and promote health.

  2024cited by this paper
• Neuroinflammation and schizophrenia – is there a link?

  2024cited by this paper
• Opioids, microglia, and temporal lobe epilepsy

  2024cited by this paper
• The Epidemiology and Global Burden of Schizophrenia.

  2023cited by this paper
• The schizophrenia syndrome, circa 2024: What we know and how that informs its nature.

  2023cited by this paper
• Oxytocin in the Treatment of Psychiatric Disorders

  2023cited by this paper
• Machine learning techniques in diagnostics and prediction of the clinical features of schizophrenia: a narrative review

  2023cited by this paper
• Morphological and transcriptomic analyses of stem cell-derived cortical neurons reveal mechanisms underlying synaptic dysfunction in schizophrenia

  2023cited by this paper
• Artificial intelligence technologies and compassion in healthcare: A systematic scoping review

  2023cited by this paper
• Oxytocin as neuro-hormone and neuro-regulator exert neuroprotective properties: A mechanistic graphical review.

  2023cited by this paper
• Pineal Abnormalities in Psychosis and Mood Disorders: A Systematic Review

  2023cited by this paper
• Angiotensin II–Mediated Neuroinflammation in the Hippocampus Contributes to Neuronal Deficits and Cognitive Impairment in Heart Failure Rats

  2023cited by this paper
• Advancement in Beneficial Effects of AVE 0991: A Brief Review.

  2023cited by this paper
• Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment

  2023cited by this paper
• Therapeutic use of melatonin in schizophrenia: A systematic review

  2021cited by this paper
• Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment

  2021cited by this paper
• Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials

  2021cited by this paper
• Oxytocin levels in individuals with schizophrenia are high in cerebrospinal fluid but low in serum: A systematic review and meta-analysis

  2021cited by this paper
• Angiotensin-(1-7) and Mas receptor in the brain

  2021cited by this paper
• An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia

  2021cited by this paper
• Melatonin and melatonin‐agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta‐analysis

  2021cited by this paper
• Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review

  2021cited by this paper
• Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression

  2020cited by this paper
• The melatonin metabolite N1‐acetyl‐5‐methoxykynuramine facilitates long‐term object memory in young and aging mice

  2020cited by this paper
• Cannabis as entheogen: survey and interview data on the spiritual use of cannabis

  2020cited by this paper
• Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies

  2020cited by this paper
• Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits

  2020cited by this paper
• Generation and Characterization of Induced Pluripotent Stem Cells from Mononuclear Cells in Schizophrenic Patients

  2019cited by this paper
• Structural Insights into CB1 Receptor Biased Signaling

  2019cited by this paper
• Renin-angiotensin system and Alzheimer's disease pathophysiology: From the potential interactions to therapeutic perspectives.

  2019cited by this paper
• The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review

  2019cited by this paper
• Pineal gland and schizophrenia: A systematic review and meta-analysis.

  2019cited by this paper
• Neurosteroids as regulators of neuroinflammation.

  2019cited by this paper
• ECT in schizophrenia: a review of the evidence

  2018cited by this paper
• RAS in the Central Nervous System: Potential Role in Neuropsychiatric Disorders.

  2018cited by this paper
• Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

  2017cited by this paper
• GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies

  2017cited by this paper
• Potential of Oxytocin in the Treatment of Schizophrenia

  2016cited by this paper
• Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia

  2016cited by this paper
• Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

  2015cited by this paper
• Cannabinoids and Schizophrenia: Risks and Therapeutic Potential

  2015cited by this paper
• Melatonin and brain inflammaging.

  2015cited by this paper
• The role of oxytocin and vasopressin in emotional and social behaviors.

  2014cited by this paper
• Sleep and circadian rhythm dysregulation in schizophrenia.

  2013cited by this paper
• Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale

  2013cited by this paper
• The Angiotensin-Melatonin Axis

  2013cited by this paper
• Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects

  2012cited by this paper
• Oxytocin in schizophrenia: a review of evidence for its therapeutic effects

  2012cited by this paper
• The therapeutic potential of cannabis and cannabinoids.

  2012cited by this paper
• Exposure to Prenatal Infection and Risk of Schizophrenia

  2011cited by this paper
• Involvement of alpha-MSH in the social isolation induced anxiety- and depression-like behaviors in rat.

  2010cited by this paper
• Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells.

  2009cited by this paper
• [New pharmacological approaches to the treatment of schizophrenia].

  2009cited by this paper
• Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity

  2009cited by this paper
• Neurocognitive deficits and prefrontal cortical atrophy in patients with schizophrenia.

  2008cited by this paper
• Melatonin, consciousness, and traumatic stress

  2008cited by this paper
• Role of alpha-melanocyte stimulating hormone and melanocortin 4 receptor in brain inflammation.

  2008cited by this paper
• Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies.

  2007cited by this paper
• Randomized controlled trials for schizophrenia: study designs targeted to distinct goals.

  2007cited by this paper
• Towards a muscarinic hypothesis of schizophrenia

  2007cited by this paper
• Investigation of hallucinogenic and related β-carbolines

  1998cited by this paper
• Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.

  1997cited by this paper
• Choline acetyltransferase in schizophrenia.

  1993cited by this paper
• Effects of Tetrahydrocannabinol on Melatonin Secretion in Man

  1986cited by this paper
• Brain tryptophan metabolism in schizophrenia: A post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects

  1979cited by this paper
• CLINICS 2011;66(5):837-841 DOI:10.1590/S1807-59322011000500021

  year unknowncited by this paper

• No citing papers are available for this paper.